ME - 23andMe Holding Co. Stock Price, Fair Value and News

$4.00

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ME Price Action

Last 7 days

-13.0%

Last 30 days

-14.9%

Last 90 days

370.6%

Trailing 12 Months

-46.4%

ME RSI Chart

ME Valuation

Market Cap

109.9M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

0.63

EV/EBITDA

-0.2

Price/Free Cashflow

-0.71

ME Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ME Fundamentals

ME Revenue

Revenue (TTM)

174.9M

Rev. Growth (Yr)

-37.1%

Rev. Growth (Qtr)

-43.7%

ME Earnings

Earnings (TTM)

-235.3M

Earnings Growth (Yr)

65.67%

Earnings Growth (Qtr)

76.02%

ME Profitability

Operating Margin

53.29%

EBT Margin

-241.01%

Return on Equity

549.03%

Return on Assets

-163.04%

Free Cashflow Yield

-141.75%

ME Investor Care

Shares Dilution (1Y)

10.86%

Diluted EPS (TTM)

-9.46

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	189.9M	174.9M	0	0
2024	219.6M	199.2M	193.3M	208.8M
2023	299.5M	295.8M	270.2M	248.0M
2022	271.9M	277.2M	297.6M	307.7M
2021	243.9M	255.1M	258.5M	259.9M
2020	305.5M	290.1M	274.7M	259.3M
2019	440.9M	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

CEO	Ms. Anne Wojcicki
WEBSITE	23andme.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	758

23andMe Holding Co. Frequently Asked Questions

What is the ticker symbol for 23andMe Holding Co.? What does ME stand for in stocks?

ME is the stock ticker symbol of 23andMe Holding Co.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 23andMe Holding Co. (ME)?

As of Mon Aug 11 2025, market cap of 23andMe Holding Co. is 109.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ME stock?

You can check ME's fair value in chart for subscribers.

Is 23andMe Holding Co. a good stock to buy?

The fair value guage provides a quick view whether ME is over valued or under valued. Whether 23andMe Holding Co. is cheap or expensive depends on the assumptions which impact 23andMe Holding Co.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ME.

What is 23andMe Holding Co.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Aug 11 2025, ME's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 0.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ME PE ratio will change depending on the future growth rate expectations of investors.